BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics. Its technology aims to improve accuracy in detecting fetal aneuploidies, microdeletions, and single-gene disorders from maternal blood samples by reducing measurement noise and enabling precise digital quantification. The company provides testing services and partners with clinical laboratories, healthcare providers, and research organizations to implement its assays in clinical and research settings.
In support of clinical adoption, BillionToOne focuses on analytical validation, clinical studies, and building laboratory processes that integrate its single-molecule counting approach into standard diagnostic pipelines. The company positions its platform as complementary to existing sequencing and molecular methods, emphasizing improved detection of low-frequency variants and potential reductions in false positives that can drive follow-up invasive procedures.
BillionToOne serves the healthcare and clinical diagnostics market, primarily through collaborations and laboratory channels. Its management and scientific teams are oriented toward translating advanced genomic measurement techniques into deployable clinical tests, with ongoing efforts to expand the clinical utility and accessibility of its assays through partnerships and regulatory and clinical validation activities.
AI Generated. May Contain Errors.
